Skip to content

LIDDS appoints Matthew Lindon as acting CEO

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson.

In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st.

Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS’ business and drive forward a strong business development strategy.

“Matthew’s appointment is recognition of the need for continuity in executing the strategic plans developed in the last year”, says Pontus Ottosson, chairman of LIDDS. “Matthew has been central to our strategy, knows the business well, and has the right leadership capabilities to drive LIDDS forward”.

“Like many small biotech companies LIDDS has faced headwinds in recent times, and during the last months we’ve restructured the business to adapt to these challenges” says Matthew Lindon. “Despite this, I see in LIDDS a company with an effective technology in NanoZolid®, and a portfolio of clinical stage assets, with proven modes of action. We must remain focused and continue to deliver on our strategy to find partners for all of LIDDS’ assets, to maximise value in all aspects of the business”.

Anders will remain with LIDDS until August 31st to ensure a smooth transition.